COYA | Coya Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.15 - 5.63
52 Week Range	4.75 - 10.69
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	97,359
Average Volume	92,214
Shares Outstanding	16,707,441
Market Cap	87,546,991
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-12-29

Valuation
Profitability
Growth
Health
P/E Ratio	-8.06
Forward P/E Ratio	-3.70
EPS	-0.65
1YR Price Target	9.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	COYA

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

COYA's peers: CUE, LTRN, FENC, ELYM, ABOS, INZY, TERN, DAWN, GRTX, CGTX, TFFP, TCRX, DRMA, NAMSW, CNTA, STRO, OPT, HLVX, GANX, LIFE, INAB

*Chart delayed

Analyzing fundamentals for COYA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see COYA Fundamentals page.

Watching at COYA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on COYA Technicals page.